NEW YORK – Expedeon has entered into a commercial agreement with Sona Nanotech with the intention of addressing limitations in the development of multiplex point-of-care lateral flow diagnostic tests.
Expedeon is a UK-based company specializing in development of tools for biological research, diagnostics, and drug discovery, while Sona is a Halifax, Canada-based maker of gold nanorod technologies for diagnostic applications and drug delivery.
Under the terms of the agreement, Expedeon will provide gold nanoparticles, bioconjugation technologies, and expertise, and Sona will offer its lateral flow assay development services.
Lateral flow assays are among the most widely used POC diagnostic tests due to their rapidity, ease of use, long-term storage, and application in resource-limiting settings, the firms noted in a statement. The firms expect their collaboration to enable simultaneous detection of multiple analytes with distinct visual differences between the test lines in a fully scalable, transferable, and cost-effective way.
Expedeon has previously signed deals to provide colloidal gold technology — supplied in an aqueous suspension of uniform, spherical metallic nanoparticles that can conjugate to antibodies and antigens — to Malaysia-based Reszon Diagnostics International and South Korean diagnostics firm PaxGenBio.